Prediction of Core Signaling Pathway by Using Diffusion- and Perfusion-based MRI Radiomics and Next-generation Sequencing in Isocitrate Dehydrogenase Wild-type Glioblastoma.

Background Next-generation sequencing (NGS) enables highly sensitive cancer genomics analysis, but its clinical implications for therapeutic options from imaging-based prediction have been limited. Purpose To predict core signaling pathways in isocitrate dehydrogenase (IDH) wild-type glioblastoma by using diffusion and perfusion MRI radiomics and NGS. Materials and Methods The radiogenomics model was developed by using retrospective patients with glioma who underwent NGS and anatomic, diffusion-, and perfusion-weighted imaging between March 2017 and February 2019. For testing model performance in predicting core signaling pathway, patients with IDH wild-type glioblastoma from a retrospective analysis from a registry (ClinicalTrials.gov NCT02619890) were evaluated. Radiogenomic feature selection was performed by using t tests, least absolute shrinkage and selection operator penalization, and random forest. Combining radiogenomic features, age, and location, the performance of predicting receptor tyrosine kinase (RTK), tumor protein p53 (P53), and retinoblastoma 1 pathways was evaluated by using the area under the receiver operating characteristic curve (AUC). Results There were 120 patients (52 years ± 13 [standard deviation]; 61 women) who were evaluated. Eighty-five patients (51 years ± 13; 43 men) were in the training set and 35 patients with IDH wild-type glioblastoma (56 years ± 12; 19 women) were in the validation set. Radiogenomics model identified 71 features in the RTK, 17 features in P53, and 35 features in the retinoblastoma pathway. The combined model showed better performance than anatomic imaging-based prediction in the RTK (P = .03) and retinoblastoma (P = .03) and perfusion imaging-based prediction in the P53 pathway (P = .04) in the training set. AUC values of the combined model for the prediction of core signaling pathways were 0.88 (95% confidence interval [CI]: 0.74, 1) for RTK, 0.76 (95% CI: 0.59, 0.92) for P53, and 0.81 (95% CI: 0.64, 0.97) for retinoblastoma in the validation set. Conclusion A diffusion- and perfusion-weighted MRI radiomics model can help characterize core signaling pathways and potentially guide targeted therapy for isocitrate dehydrogenase wild-type glioblastoma. © RSNA, 2019 Online supplemental material is available for this article.

[1]  Ho Sung Kim,et al.  Reproducibility and Generalizability in Radiomics Modeling: Possible Strategies in Radiologic and Statistical Perspectives , 2019, Korean journal of radiology.

[2]  Fanny Orlhac,et al.  Validation of A Method to Compensate Multicenter Effects Affecting CT Radiomics. , 2019, Radiology.

[3]  David T. W. Jones,et al.  Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma , 2018, Neuro-oncology.

[4]  Yan Wang,et al.  Multimodal 3D DenseNet for IDH Genotype Prediction in Gliomas , 2018, Genes.

[5]  Simon A Keek,et al.  A review on radiomics and the future of theranostics for patient selection in precision medicine. , 2018, The British journal of radiology.

[6]  H. Zaidi,et al.  Radiogenomics is the future of treatment response assessment in clinical oncology. , 2018, Medical physics.

[7]  Tae Min Kim,et al.  Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma , 2018, European Radiology.

[8]  Zev A. Binder,et al.  Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1 , 2018, Scientific Reports.

[9]  S. Park,et al.  Methodologic Guide for Evaluating Clinical Performance and Effect of Artificial Intelligence Technology for Medical Diagnosis and Prediction. , 2018, Radiology.

[10]  M. Paolillo,et al.  Glioblastoma under Siege: An Overview of Current Therapeutic Strategies , 2018, Brain sciences.

[11]  J. Pearson,et al.  Targeting cellular pathways in glioblastoma multiforme , 2017, Signal Transduction and Targeted Therapy.

[12]  A. Tamimi,et al.  Epidemiology and Outcome of Glioblastoma , 2017 .

[13]  Mahlon D. Johnson,et al.  The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma , 2017, Journal of Neuro-Oncology.

[14]  Ginu A. Thomas,et al.  Distinct Radiomic Phenotypes Define Glioblastoma TP53-PTEN-EGFR Mutational Landscape. , 2017, Neurosurgery.

[15]  K. Ligon,et al.  Glioblastoma targeted therapy: updated approaches from recent biological insights , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Peter Balter,et al.  Delta-radiomics features for the prediction of patient outcomes in non–small cell lung cancer , 2017, Scientific Reports.

[17]  Martin Sill,et al.  Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. , 2016, Radiology.

[18]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[19]  M. Sughrue,et al.  Glioblastoma: new therapeutic strategies to address cellular and genomic complexity , 2015, Oncotarget.

[20]  Rivka R Colen,et al.  Imaging genomics of Glioblastoma: state of the art bridge between genomics and neuroradiology. , 2015, Neuroimaging clinics of North America.

[21]  E. Kohn,et al.  The MAPK pathway across different malignancies: A new perspective , 2014, Cancer.

[22]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[23]  S. Plevritis,et al.  Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. , 2014, Radiology.

[24]  Neema Jamshidi,et al.  Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. , 2013, Radiology.

[25]  L. Parada,et al.  Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells , 2012, Cell.

[26]  Ferenc A. Jolesz,et al.  Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme , 2011, PloS one.

[27]  S. Gabriel,et al.  Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.

[28]  B. Neyns,et al.  Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[30]  I. Conboy,et al.  Aging of signal transduction pathways, and pathology. , 2008, Experimental cell research.

[31]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[32]  Anssi Auvinen,et al.  Incidence of gliomas by anatomic location. , 2007, Neuro-oncology.

[33]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[34]  T. Jiang,et al.  MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis , 2017, European Radiology.

[35]  Benjamin M. Ellingson,et al.  Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics , 2014, Current Neurology and Neuroscience Reports.